Sangamo Therapeutics, Inc.
SGMO
$0.15
-$0.02-12.73%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -45.80% | -31.57% | -37.13% | 565.52% | 239.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.80% | -31.57% | -37.13% | 565.52% | 239.92% |
| Cost of Revenue | 11.63% | 1.21% | -24.54% | -37.96% | -50.06% |
| Gross Profit | -108.80% | -36.62% | 16.92% | 85.50% | 79.56% |
| SG&A Expenses | -26.44% | -22.00% | -23.03% | -28.76% | -19.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.29% | -5.44% | -24.15% | -35.75% | -43.75% |
| Operating Income | -36.71% | -9.93% | 19.10% | 71.07% | 66.10% |
| Income Before Tax | -55.81% | -25.88% | 18.91% | 74.45% | 76.11% |
| Income Tax Expenses | -370.55% | -240.12% | -3,583.33% | -116.50% | 97.17% |
| Earnings from Continuing Operations | -55.23% | -25.52% | 19.23% | 74.64% | 75.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.23% | -25.52% | 19.23% | 74.64% | 75.78% |
| EBIT | -36.71% | -9.93% | 19.10% | 71.07% | 66.10% |
| EBITDA | -40.39% | -11.70% | 18.82% | 71.87% | 66.25% |
| EPS Basic | -1.86% | 13.16% | 39.96% | 79.35% | 79.75% |
| Normalized Basic EPS | 6.61% | 15.59% | 37.33% | 75.77% | 71.21% |
| EPS Diluted | 0.67% | 14.76% | 39.74% | 78.68% | 79.25% |
| Normalized Diluted EPS | 7.05% | 15.90% | 37.49% | 75.61% | 71.07% |
| Average Basic Shares Outstanding | 52.90% | 39.41% | 28.75% | 21.20% | 18.79% |
| Average Diluted Shares Outstanding | 51.82% | 38.38% | 27.75% | 22.01% | 19.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |